Under construction – not a live service
Sign in

2024-519491-60-00Not yet recruitingPhase 1/2

An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases

Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Aug 2026

Next steps

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
36 (estimated)
First submitted
27 Apr 2026
Start date
1 Jul 2026
Lead sponsor
Universitaetsklinikum Tuebingen AöR
EU CT number
2024-519491-60-00

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 36
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose autoimmune disease has come back or has not responded to earlier treatment. It tests a CAR-T cell therapy, UKT-CART19.1.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Relapsed or refractory (returned or not responding to treatment) autoimmune disease: ANCA associated vasculitis, immune thrombocytopenic purpura, multiple sclerosis, rheumatoid arthritis, pemphigus vulgaris, systemic sclerosis, or inflammatory idiopathic myositis.

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Universitaetsklinikum Tuebingen AöRTuebingenGermanyNot yet recruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.